Filtered By:
Vaccination: Veterinary Vaccinations

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 406 results found since Jan 2013.

Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):207-214. doi: 10.18502/ijaai.v21i2.9228.ABSTRACTUtilizing subunit vaccines is one of the strategies to address influenza infection. Recent innovations have focused on high doses of vaccine antigens and immune enhancers or adjuvant to induce more robust and long-lasting immune responses. Here, an effect of the B cell-activating factor receptor (BAFF-R) to increase the magnitude and durability of immune responses of the recombinant HA1 (rHA1) protein against the H1N1 influenza virus was studied. The HA1 protein and the effector domain of BAFF-R were expressed in the pET-28a (+...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Seyedeh Mahsa Bagheri Yazdi Shahla Shahsavandi Fatemeh Fotouhi Majid Tebianian Mohammad Majid Ebrahimi Source Type: research

Agent-based Modeling of Tumor and Immune System Interactions in Combinational Therapy with Low-dose 5-fluorouracil and Dendritic Cell Vaccine in Melanoma B16F10
This study is designed to present an agent-based model (ABM) to simulate the interactions between tumor cells and the immune system in the melanoma model. The Myeloid-derived Suppressor Cells (MDSCs) and dendritic cells (DCs) are considered in this model as immunosuppressive and antigen-presenting agents respectively. The animal experiment was performed on 68 B16F10 melanoma tumor-bearing C57BL/6 female mice to collect dynamic data for ABM implementation and validation. Animals were divided into 4 groups; group 1 was control (no treatment) while groups 2 and 3 were treated with DC vaccine and low-dose 5- fluorouracil (5-FU...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Sarah Rahbar Sajad Shafiekhani Armin Allahverdi Arezoo Jamali Nasim Kheshtchin Maryam Ajami Zahra Mirsanei Sima Habibi Bahador Makkiabadi Jamshid Hadjati Amir Homayoun Jafari Source Type: research

Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):207-214. doi: 10.18502/ijaai.v21i2.9228.ABSTRACTUtilizing subunit vaccines is one of the strategies to address influenza infection. Recent innovations have focused on high doses of vaccine antigens and immune enhancers or adjuvant to induce more robust and long-lasting immune responses. Here, an effect of the B cell-activating factor receptor (BAFF-R) to increase the magnitude and durability of immune responses of the recombinant HA1 (rHA1) protein against the H1N1 influenza virus was studied. The HA1 protein and the effector domain of BAFF-R were expressed in the pET-28a (+...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Seyedeh Mahsa Bagheri Yazdi Shahla Shahsavandi Fatemeh Fotouhi Majid Tebianian Mohammad Majid Ebrahimi Source Type: research

Agent-based Modeling of Tumor and Immune System Interactions in Combinational Therapy with Low-dose 5-fluorouracil and Dendritic Cell Vaccine in Melanoma B16F10
This study is designed to present an agent-based model (ABM) to simulate the interactions between tumor cells and the immune system in the melanoma model. The Myeloid-derived Suppressor Cells (MDSCs) and dendritic cells (DCs) are considered in this model as immunosuppressive and antigen-presenting agents respectively. The animal experiment was performed on 68 B16F10 melanoma tumor-bearing C57BL/6 female mice to collect dynamic data for ABM implementation and validation. Animals were divided into 4 groups; group 1 was control (no treatment) while groups 2 and 3 were treated with DC vaccine and low-dose 5- fluorouracil (5-FU...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Sarah Rahbar Sajad Shafiekhani Armin Allahverdi Arezoo Jamali Nasim Kheshtchin Maryam Ajami Zahra Mirsanei Sima Habibi Bahador Makkiabadi Jamshid Hadjati Amir Homayoun Jafari Source Type: research

Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):207-214. doi: 10.18502/ijaai.v21i2.9228.ABSTRACTUtilizing subunit vaccines is one of the strategies to address influenza infection. Recent innovations have focused on high doses of vaccine antigens and immune enhancers or adjuvant to induce more robust and long-lasting immune responses. Here, an effect of the B cell-activating factor receptor (BAFF-R) to increase the magnitude and durability of immune responses of the recombinant HA1 (rHA1) protein against the H1N1 influenza virus was studied. The HA1 protein and the effector domain of BAFF-R were expressed in the pET-28a (+...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Seyedeh Mahsa Bagheri Yazdi Shahla Shahsavandi Fatemeh Fotouhi Majid Tebianian Mohammad Majid Ebrahimi Source Type: research

Agent-based Modeling of Tumor and Immune System Interactions in Combinational Therapy with Low-dose 5-fluorouracil and Dendritic Cell Vaccine in Melanoma B16F10
This study is designed to present an agent-based model (ABM) to simulate the interactions between tumor cells and the immune system in the melanoma model. The Myeloid-derived Suppressor Cells (MDSCs) and dendritic cells (DCs) are considered in this model as immunosuppressive and antigen-presenting agents respectively. The animal experiment was performed on 68 B16F10 melanoma tumor-bearing C57BL/6 female mice to collect dynamic data for ABM implementation and validation. Animals were divided into 4 groups; group 1 was control (no treatment) while groups 2 and 3 were treated with DC vaccine and low-dose 5- fluorouracil (5-FU...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Sarah Rahbar Sajad Shafiekhani Armin Allahverdi Arezoo Jamali Nasim Kheshtchin Maryam Ajami Zahra Mirsanei Sima Habibi Bahador Makkiabadi Jamshid Hadjati Amir Homayoun Jafari Source Type: research

Modulation of Immune Responses Against HA1 Influenza Vaccine Candidate by B-lymphocyte Stimulator Cytokine in Mice
Iran J Allergy Asthma Immunol. 2022 Apr 11;21(2):207-214. doi: 10.18502/ijaai.v21i2.9228.ABSTRACTUtilizing subunit vaccines is one of the strategies to address influenza infection. Recent innovations have focused on high doses of vaccine antigens and immune enhancers or adjuvant to induce more robust and long-lasting immune responses. Here, an effect of the B cell-activating factor receptor (BAFF-R) to increase the magnitude and durability of immune responses of the recombinant HA1 (rHA1) protein against the H1N1 influenza virus was studied. The HA1 protein and the effector domain of BAFF-R were expressed in the pET-28a (+...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Seyedeh Mahsa Bagheri Yazdi Shahla Shahsavandi Fatemeh Fotouhi Majid Tebianian Mohammad Majid Ebrahimi Source Type: research

Agent-based Modeling of Tumor and Immune System Interactions in Combinational Therapy with Low-dose 5-fluorouracil and Dendritic Cell Vaccine in Melanoma B16F10
This study is designed to present an agent-based model (ABM) to simulate the interactions between tumor cells and the immune system in the melanoma model. The Myeloid-derived Suppressor Cells (MDSCs) and dendritic cells (DCs) are considered in this model as immunosuppressive and antigen-presenting agents respectively. The animal experiment was performed on 68 B16F10 melanoma tumor-bearing C57BL/6 female mice to collect dynamic data for ABM implementation and validation. Animals were divided into 4 groups; group 1 was control (no treatment) while groups 2 and 3 were treated with DC vaccine and low-dose 5- fluorouracil (5-FU...
Source: Iranian Journal of Allergy, Asthma and Immunology - May 1, 2022 Category: Allergy & Immunology Authors: Sarah Rahbar Sajad Shafiekhani Armin Allahverdi Arezoo Jamali Nasim Kheshtchin Maryam Ajami Zahra Mirsanei Sima Habibi Bahador Makkiabadi Jamshid Hadjati Amir Homayoun Jafari Source Type: research

Prefusion Coronavirus Spike Proteins and Their Use
Coronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic approaches.CoV spike (S) prote...
Source: NIH OTT Licensing Opportunities - April 28, 2022 Category: Research Authors: ott8admin Tags: Collaboration Sought NIAID Infectious Disease Source Type: research

Defining the risk of SARS-CoV-2 variants on immune protection
We report the development of reagents, methodologies, models, and pivotal findings facilitated by this collaborative approach and identify future challenges. This program serves as a template for the response against rapidly evolving pandemic pathogens by monitoring viral evolution in the human population to identify variants that could erode the effectiveness of countermeasures.PMID:35361968 | DOI:10.1038/s41586-022-04690-5
Source: Cancer Control - April 1, 2022 Category: Cancer & Oncology Authors: Marciela M DeGrace Elodie Ghedin Matthew B Frieman Florian Krammer Alba Grifoni Arghavan Alisoltani Galit Alter Rama R Amara Ralph S Baric Dan H Barouch Jesse D Bloom Louis-Marie Bloyet Gaston Bonenfant Adrianus C M Boon Eli A Boritz Debbie L Bratt Traci Source Type: research

Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model
Wormwood (Artemisia) pollen is among the top 10 aeroallergens globally that cause allergic rhinitis and bronchial asthma. Allergen-specific immunotherapy (ASIT) is the gold standard for treating patients with allergic rhinitis, conjunctivitis, and asthma. A significant disadvantage of today’s ASIT methods is the long duration of therapy and multiplicity of allergen administrations. The goal of this study was to undertake a pilot study in mice of a novel ultrashort vaccine immunotherapy regimen incorporating various adjuvants to assess its ability to treat allergic bronchial asthma caused by wormwood pollen.We evaluated i...
Source: Frontiers in Immunology - March 15, 2022 Category: Allergy & Immunology Source Type: research

NIDCR's Spring 2022 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2022 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NIDCR News Science Advances   NIDCR News NIH & NIDCR Release “Oral Health in America: Advances and Challenges” In December, NIDCR announced the release of a report that provides a comprehensive snapshot of oral health in America, detailing 20 years of advances and challenges and drawing on data from public research and evidence-based practices. For more ...
Source: NIDCR Science News - March 3, 2022 Category: Dentistry Source Type: news

Nasal Vaccines Could Help Stop COVID-19 From Spreading —If Scientists Can Get Them Right
When SARS-CoV-2, the virus that causes COVID-19, infiltrates the body, it typically enters through the nose or mouth, then takes root and begins replicating. But what if it could never get a foothold in the upper airways? That’s the promise of nasal COVID-19 vaccines, which are meant to prevent infection by blocking the virus at its point of entry. There is not yet a nasal COVID-19 vaccine available in the U.S.—and it’s not clear if or when there will be—but multiple research teams in the U.S., including the National Institute of Allergy and Infectious Diseases, and abroad are working on them. Russi...
Source: TIME: Health - February 15, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Reduced SARS-CoV-2 Vaccine Response in Patients Treated with Biologic Therapies for Asthma and Atopic Dermatitis
SARS-CoV-2 vaccines confer great protection against COVID-19 in healthy adults, but it is unknown how patients with severe asthma and atopic dermatitis on biologic therapies respond despite animal data suggesting a lower response.
Source: Journal of Allergy and Clinical Immunology - February 1, 2022 Category: Allergy & Immunology Authors: Martin Runnstrom, Andrea Morrison-Porter, Mayuran Ravindran, Hannah Quehl, Richard Ramonell, Matthew Woodruff, Merin Kalangara, Fabliha Anam, Robert Swerlick, Colin Swenson, Carmen Polito, Wendy Neveu, Rahulkumar Patel, Caroline Kim, Ian Hentenaar, Zhenxi Source Type: research